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ABSTRACT
Background: 2-Amino-2-[2-(4-octylphenyl)ethyl] propane-1,3-diol hydro-
hloride (FTY720) is a novel agent with protective effect on several markers of liver
njury. It is a chemical substance derived by modifying myriocin from the ascomycete
saria sinclairii. It has been reported that FTY720 is able to treat autoimmune
ncephalomyelitis, renal cancer, asthma, and multiple sclerosis. More potent clinical
pplications of FTY720 need to be investigated.
Objective: The aim of this study was to evaluate the protective effect of
FTY720 on several markers of experimental liver injury and to investigate the
possible mechanism of action.
Methods: Concanavalin A (Con A) at a dose of 15 mg/kg was intravenously.
injected in mice, and 10 days before the Con A challenge, 1 mg/kg, 3 mg/kg, and
6 mg/kg of FTY720 were administered to mice. The liver injury was monitored
biochemically by measuring serum alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) and tumor necrosis factor- (TNF-) levels. TNF- and
uclear factor-B (NF-B) in liver tissue were detected by Western blot analysis.
Results: FTY720, when administered intragastrically for 10 days in mice with
Con A–induced liver injury, dose-dependently reduced serum ALT and AST and
TNF- levels. The differences were statistically significant (P  0.05). It was also
found that FTY720 decreases TNF- and NF-B protein expression in liver tissue.
Conclusions: FTY720 is able to improve several markers of Con A–induced
iver injury in mice, including serum ALT, serum AST, TNF-, and NF-B, which
ight be at least in part related to its ability to reduce TNF-/NF-B cascade
activity. (Curr Ther Res Clin Exp. 2012;73:140–149) © 2012 Elsevier HS Journals,
Inc. All rights reserved.
Key words: concanavalin A, FTY720, liver injury, nuclear factor-B, tumor
necrosis factor-.
INTRODUCTION
FTY720, 2-amino-2-[2-(4-octylphenyl)ethyl] propane-1,3-diol hydrochloride, is a
novel agent with a protective effect on several markers of liver injury. It is a chemical
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X.-D. Yin et al.substance derived by modifying myriocin (ISP-1) from the ascomycete Isaria sinclai-
rii.1–3 Its chemical structure is completely different from that of conventional
rotective agents of liver injury. Although I sinclairii has been widely used in Chinese
raditional medicine, administration of ISP-1 produces severe digestive disorders,
esulting in death in experimental animals. Because of the potent liver injury
rotective activity of ISP-1 in vitro, synthetic modifications were made to generate
ess toxic, more active compounds. One of these new compounds is FTY720.4
It has been reported that FTY720 could prolong allograft survival in a variety of
ransplant models without impairing host immune responses.1,5,6 There are also
reports that FTY720 is able to treat autoimmune encephalomyelitis,7 renal cancer,8
asthma,9 and multiple sclerosis.10,11 However, there are no reports about the effect of
FTY720 on liver injury except our primary study reported in 2005.12
Concavanalin A (Con A) activates T cells. A low dose of Con A is able to inhibit
lebsiella pneumoniae–induced liver injury and bacteremia by decreasing the bacterial
urden in the liver, but the well-known activity of Con A is the induction of
-cell–mediated hepatitis. A Con A injection in mice results in dose-dependent
mmune-mediated liver injury. After in vivo exposure of Con A, different distinct cell
ypes become activated, which eventually leads to the destruction of liver cells.13 The
high affinity of Con A to the hepatocyte sinus seems to be specifically involved in
attracting cells of the immune system to the liver.14,15 Several reports contributed to
our current understanding of this immune-mediated process, and there is evidence
that these mechanisms are also relevant for the initial events during the pathophys-
iology of liver diseases found in humans such as autoimmune and viral hepatitis.16,17
The aims of this study were to evaluate the protective effect of FTY720, a novel




Male mice (albino Swiss) weighing 18 to 22 g, were obtained from the Department
f Experimental Animals, Tianjin Medical University, Tianjin, China. Animals
eceived humane care according to the criteria outlined in the Guide for the Care and
se of Laboratory Animals prepared by the Academy of Sciences and published by the
ational Institutes of Health. Mice were maintained under controlled conditions
22°C, 55% humidity, 12-hour day/night cycles) and were fed a standard laboratory
how until the experiments were completed.
Drug
FTY720 was supplied as dry powder from Hangzhou Zhongmei Hua-Dong
harmaceutical Co Ltd (Zheziang, China) and was dissolved in physiologic saline
olution.
Experiment Design






Current Therapeutic Researchintravenously injected in mice at a dose of 20 mg/kg, 15 mg/kg, and 10 mg/kg. Only
the Con A dose of 15 mg/kg was selected for final analysis, FTY720 was used in
doses of 1 mg/kg, 3 mg/kg, and 6 mg/kg. Serum samples from individual mice
were obtained from the fundus oculi vein at indicated time points after the Con
A challenge. Liver injury was monitored biochemically by measuring serum
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. For
the histopathologic evaluation, mice were killed at indicated time points after the
Con A challenge. Liver tissue was fixed in 10% neutral-buffered formalin and
embedded in paraffin. Sections 5 m thick were stained with hematoxylin and
eosin (HE) for evaluation with light microscopy. The mice in Figures 1 and 2
elonged to the same group, the mice in Figures 4, 5, and 6 belonged to the same
roup, and the mice in Figures 7 and 3 belonged to their own group, respec-























































Figure 1. Time–concentration curve of concanavalin A (Con A)–induced liver injury. Serum
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activity
at various times after the ConA challenge. Mice were fasted for 12 hours before
the ConA challenge, and serum ALT or AST activity was measured, as described



















Figure 2. Time–concentration curve of concanavalin A (Con A)–induced liver injury. Serum
tumor necrosis factor- (TNF-) levels at various times after the Con A chal-
lenge. Mice were fasted for 12 hours before the Con A challenge, and serum
TNF- levels were measured as described in the Materials and Methods. Ten







X.-D. Yin et al.Biochemical Analysis
Kits to measure ALT and AST levels were purchased from Sigma-Aldrich.
Serum TNF- Levels
The serum levels of TNF- were monitored using a commercially available ELISA
it (Chemicon International, Inc, Temecula, California). To evaluate the role of
NF- in liver injury, serum TNF- levels were determined at indicated time points
after the Con A challenge.
Western Blot Analysis
Liver cytosolic and nuclear extracts were prepared as described,18 and proteins were
uantitated with a Bradford assay. Eighty-microgram protein samples were separated
y 15% and 10% SDS-PAGE and transferred to nitrocellulose membranes (Amer-






















































































Figure 4. Serum tumor necrosis factor- (TNF-) levels after treatment with FTY720.
FTY720 treatment decreases serum TNF- levels. Blood was withdrawn 1 hour
































Figure 3. Dose-dependent curve of concanavalin A (Con A)–induced liver injury. Mice were
fasted for 12 hours and were challenged with 10, 15, and 20 mg/kg of Con A.
Animals were killed, and serum levels were measured 12 hours after the chal-










Current Therapeutic Research2 hours in 5% nonfat milk dissolved in Tris-buffered saline (BST) at room temper-
ature. TNF- and NF-B were detected with goat anti–TNF- and mouse anti–
F-B monoclonal antibodies, respectively (Santa Cruz Biotechnology, Inc, Santa
Cruz, California) at 1:300 in TBS. After an overnight incubation with a primary
antibody at 4°C, blots were washed with 0.1% Tween 20/BST (TBST), probed with
a specific secondary antibody (Santa Cruz Biotechnology, Inc), and washed again with
TBST. Proteins were visualized by enhanced chemiluminescence (Amersham Phar-
macia Biotech, Hong Kong) according to the manufacturer’s instructions.
Statistical Analysis
Results are expressed as mean (SD). All statistical calculations were performed
sing the SPSS statistical package (SPSS Inc, Chicago, Illinois); for all analyses, a t test
nd 1-way ANOVA were used to test for significance. P  0.05 was considered
tatistically significant.
RESULTS
Dose–Effect Curve of Con A–Induced Liver Injury
To ascertain the appropriate dose of Con A to induce liver injury, serum ALT
ctivity was determined before and at 12 hours after Con A (10, 15, 20 mg/kg)
hallenge. With the increasing of dose of Con A, serum ALT activity increased
imultaneously. We selected a dose of 15 mg/kg of Con A to induce liver injury in
xperiments because of deaths observed in the group receiving 20 mg/kg Con A, as
hown in Figure 3.
1 2 3 4
TNF-α
Figure 5. The effect of FTY720 on the expression of tumor necrosis factor- (TNF-) in the
liver after the concanavalin A (Con A) injection byWestern blot analysis. Liver tissue
was obtained from mice 1 hour after the Con A challenge. Four mice per group.
1: control group; 2: Con A group; 3: ConA  FTY720 1 mg/kg; 4: ConA  FTY720
3 mg/kg.
1 2 3 4 5
NF-κB P65
Figure 6. The effect of FTY720 on the expression of nuclear factor-B (NF-B) in the liver after
concanavalin A (Con A) injection by Western blot analysis. Liver tissue was ob-
tained from mice 1 hour after the Con A challenge. Four mice per group. 1: control
group; 2: Con A 15 mg/kg; 3: Con A 15 mg/kg  FTY720 1 mg/kg; 4: Con A 15












X.-D. Yin et al.Alteration of Serum Transaminase Activity in Con A–Induced Liver
Injury in Mice
Serum ALT and AST activity was examined before and at 0.5, 1, 2, 4, 6, 8, 12, and
4 hours after the Con A challenge. As shown in Figure 1, there were no changes in
erum ALT and AST activity at 0.5, 1, and 2 hours after the intravenously admin-
stered Con A (15 mg/kg) challenge. In contrast, 4 hours after the Con A challenge,
erum ALT and AST activity had dramatically increased and reached a maximum at
2 hours after the challenge. The differences were statistically significant (P  0.05).
he elevated activity is not sustained throughout recovery from Con A toxicity, and
erum ALT or AST activity begin to decrease by 24 hours after the challenge.
Alteration of Serum TNF- Levels in Con A–Induced Liver Injury in
Mice
Serum TNF- levels were measured before and at 1, 2, 4, 8, and 12 hours after the
Con A challenge. As shown in Figure 2, 1 hour after the Con A challenge, serum
TNF- levels were dramatically increased. The differences were statistically signifi-
cant (P  0.05). These increased levels are not sustained and begin to decrease by 2
hours after the challenge.
FTY720 Dramatically Decreased Liver Injury After the Con A
Challenge
Different doses of FTY720 (1 mg/kg, 3 mg/kg, and 6 mg/kg) or normal saline
olution (in the Con A group) were administered to mice for 10 days before the Con






























































































Figure 7. Effect of FTY720 on serum alanine aminotransferase (ALT) and aspartate ami-
notransferase (AST) levels in concanavalin A (Con A)–induced liver injury.
FTY720 treatment dramatically reduces circulating markers of hepatocyte in-
jury. Serum ALT and AST activity in fasted mice after 10 days of pretreatment
with FTY720 or saline solution in mice that were then challenged with 15 mg/kg
Con A. Blood was withdrawn from each mouse 12 hours after the Con A


























Current Therapeutic Researchstatistically significant (P  0.05). HE staining of liver tissue showed that in the
ontrol mice, which were treated with normal saline solution, there was no dramatic
eduction in centrilobular hepatocyte necrosis and hemorrhagic injury. In contrast,
here was maintenance of the hepatic architecture and little evidence of hepatocyte
njury when animals were treated with FTY720. Different doses of FTY720 dramat-
cally decreased circulating markers of hepatocyte injury, as shown in Figure 7.
Different Doses of FTY720 Decreased the Elevated Serum TNF-
Levels After the Con A Challenge
FTY720 (1 mg/kg, 3 mg/kg, and 6 mg/kg) or normal saline solution (in the Con
group) were administered to mice for 10 days before the Con A challenge. Then the
ice were injected with 15 mg/kg of Con A intravenously. FTY720 decreased serum
NF- levels at 1 hour after the challenge, as shown in Figure 4. The differences
ere statistically significant (P  0.05). Different doses of FTY720 dramatically
decreased circulating TNF- in liver injury.
TNF- and NF-B Expression in Liver Tissue Was Decreased by
FTY720 Treatment
Western blot analysis was used to determine TNF- expression in liver cytosol.
TY720 pretreatment down-regulates TNF- protein expression 1 hour after the Con
challenge compared with the Con A group, as shown in Figure 5. Nuclear extracts
f liver were used to determine NF-B expression. The results indicated that different
doses of FTY720 are able to decrease NF-B expression at 1 hour after the Con A
hallenge, as shown in Figure 6.
DISCUSSION
TNF- is a key inflammatory mediator secreted by macrophages that regulates
nflammatory responses and immune cell activity.19 TNF- exerts its effector actions
hrough the activation of a proinflammatory transcription factor, NF-B signaling
pathway, to regulate cell growth.20–22 It is suggested that understanding the mo-
lecular pathways that regulate whether hepatocytes survive or die is of therapeutic
importance. This could lead to the identification of novel therapeutic agents capable
of preventing cell death during liver injury. NF-B is acted as a target for developing
ew hepatoprotective drugs. It is interesting to note that some drugs with preventive
ctivation of NF-B have shown important benefits for liver damage.23
The TNF- and NF-B pathways are complex, and hence in vivo effects are likely
to be very complicated. The mechanisms of hepatotoxicity induced by a few exper-
imental drugs are not via TNF- or NF-B. Gemtuzumab is a anti-CD33 mono-
lonal antibody conjugated to a cytotoxic agent, calicheamicin. Liver injury after
emtuzumab ozogamicin infusion was usually manifested by signs of portal hyper-
ension: hepatomegaly, weight gain, ascites, and increased portal pressure. This liver
njury is termed sinusoidal obstruction syndrome (SOS).24 The hepatocyte necrosis
as caused by ischemia related to sinusoidal injury rather than to a direct toxic effect
f calicheamicin on hepatocytes. The potential mechanism by which gemtuzumab




























X.-D. Yin et al.the antibody–calicheamicin complex by Kupffer cells. On the other hand, altering
TNF- with a drug does not necessarily result in a change in liver function.
Infliximab, a TNF- monoclonal antibody, is a drug that modifies the immune
ystem and is used to treat autoimmune diseases, such as rheumatoid arthritis,
rohn’s disease, and ulcerative colitis. It has not been reported that infliximab
unctions to improve hepatic dysfunction.25
Con A injection in mice results in dose-dependent immune-mediated liver injury.
on A intravenously injected into mice at doses of 20 mg/kg, 15 mg/kg, and 10
g/kg serves as an animal model of liver injury. In fact, justification for the doses and
iming of Con A was studied. A dose of Con A 20 mg/kg would result in the death
f the animal. Con A intravenously injected in mice at a dose of 20 mg/kg once daily
or 1 week will cause fibrosis of the liver. Only the group receiving 15 mg/kg of Con
was selected for final analysis. HE staining of liver tissue showed that there is
ramatic centrilobular hepatocyte necrosis and intrasinusoidal hemorrhagic injury
fter Con A injection, which makes the intrasinusoidal hemostasis extensive enough
o induce severe hepatic injury. More typical SOS is induced in mice by monocro-
aline. Understanding basic science findings for defibrotide for liver toxicity might be
f interest and clinical value.26
The antiapoptotic effects of FTY720 are thought to contribute to its protective
ffect on several markers of liver injury; an alternative mechanism may exist and
hould be sought and further investigated in the future.27–29 This effect might occur
in liver cells as well.12 As we show in this study, FTY720 could reduce the
ncreased serum ALT and AST levels, which means that FTY720 could be a
otent anti-inflammatory agent (10 days of pretreatment with 6 mg/kg of
TY720 12 hours after liver injury in mice induced by 15 mg/kg of Con A; P 
.05 vs the control group).
We also noted that the serum TNF- level (P  0.05) and TNF- expression
ncreased in this mice model. In injured liver cells, nuclear TNF- expression was
generally associated with increased NF-B levels. The elevated serum TNF- levels
ere significantly decreased by FTY720 (10 days of pretreatment with 6 mg/kg of
TY720 1 hour after liver injury in mice induced by 15 mg/kg of Con A; P  0.05
vs control group) and the expression of TNF- and NF-B in liver cells (10 days of
retreatment with 3 and 6 mg/kg of FTY720 1 hour after liver injury in mice
nduced by 15 mg/kg of Con A; P  0.05 vs control group).
Our data suggest that the TNF-/NF-B cascade–mediated liver inflammatory
activity induced by Con A can be suppressed by FTY720. The hepatoprotective
effects of FTY720 may be related, at least in part, to its ability to reduce NF-B
activity. More work is needed to clarify this point.
CONCLUSIONS
FTY720 is able to improve several markers of liver damage, including serum ALT,
serum AST, TNF-, and NF-B, induced by Con A in mice, and this might be at
east in part due to its ability to reduce TNF-/NF-B cascade activity.
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